|
schizophrenia |
65 |
|
first-episode psychosis |
47 |
|
psychosis |
39 |
|
negative symptoms |
36 |
|
youth mental health |
36 |
|
covid-19 |
35 |
|
psychotic disorders |
35 |
|
depression |
32 |
|
early psychosis |
32 |
|
functioning |
28 |
|
predictors |
28 |
|
mental health |
25 |
|
relapse |
25 |
|
stigma |
24 |
|
early intervention |
23 |
|
first-episode schizophrenia |
22 |
|
antipsychotics |
21 |
|
cognitive impairment |
21 |
|
duration of untreated psychosis |
21 |
|
risk factors |
21 |
|
rumination |
21 |
|
social unrest |
21 |
|
cognition |
20 |
|
first episode |
20 |
|
physical activity |
20 |
|
insight |
18 |
|
medication adherence |
18 |
|
remission |
18 |
|
executive function |
17 |
|
anxiety |
16 |
|
assessment |
16 |
|
delusional disorder |
16 |
|
depressive symptoms |
16 |
|
functional outcome |
16 |
|
hong kong |
16 |
|
post-traumatic stress disorder |
16 |
|
adolescents |
15 |
|
age of onset |
15 |
|
amotivation |
15 |
|
cost-effectiveness |
15 |
|
dopamine |
15 |
|
employment |
15 |
|
psychopathology |
15 |
|
stress |
15 |
|
avolition |
14 |
|
first-episode |
14 |
|
psychiatric status rating scales |
14 |
|
quality of life |
14 |
|
schizophrenic psychology |
14 |
|
adolescent |
13 |
|
early diagnosis |
13 |
|
epidemiology |
13 |
|
mental health services |
13 |
|
outcome |
13 |
|
premorbid adjustment |
13 |
|
psychotic disorders - diagnosis |
13 |
|
self-stigma |
13 |
|
symptomatology |
13 |
|
validation study |
13 |
|
evaluation |
12 |
|
experience sampling method |
12 |
|
humans |
12 |
|
momentary positive affect |
12 |
|
recurrence |
12 |
|
resilience |
12 |
|
adherence |
11 |
|
caregivers |
11 |
|
diminished expression |
11 |
|
long-term outcomes |
11 |
|
longitudinal follow-up |
11 |
|
maintenance treatment |
11 |
|
medical sciences |
11 |
|
pattern glare |
11 |
|
perceptual distortions |
11 |
|
prevalence |
11 |
|
processing speed |
11 |
|
prospective follow-up |
11 |
|
psychiatry and neurology |
11 |
|
self-reference |
11 |
|
young people |
11 |
|
youth |
11 |
|
cognitive function |
10 |
|
cognitive functions |
10 |
|
community-based intervention |
10 |
|
disengagement |
10 |
|
double blind |
10 |
|
f-dopa |
10 |
|
female |
10 |
|
maintenance |
10 |
|
positron emission tomography |
10 |
|
randomized controlled trial |
10 |
|
recovery |
10 |
|
relapse prevention |
10 |
|
sex difference |
10 |
|
stereotyping |
10 |
|
striatal dopamine capacity synthesis |
10 |
|
treatment adherence |
10 |
|
youth-friendly |
10 |
|
affect |
9 |
|
antipsychotic agents - therapeutic use |
9 |
|
delusions |
9 |
|
early medical intervention - methods - trends |
9 |
|
epidemiological youth |
9 |
|
esm |
9 |
|
hallucination |
9 |
|
health education - methods |
9 |
|
ideas of reference |
9 |
|
internalized stigma |
9 |
|
intervention |
9 |
|
life events |
9 |
|
loneliness |
9 |
|
mental health services - trends |
9 |
|
momentary assessment |
9 |
|
motivational deficits |
9 |
|
omicron |
9 |
|
program development |
9 |
|
psychotic disorders - therapy |
9 |
|
psychotic-like experiences |
9 |
|
public stigma |
9 |
|
smartphone overuse |
9 |
|
social context |
9 |
|
traumatic events |
9 |
|
treatment outcome |
9 |
|
brain - ultrastructure |
8 |
|
cluster analysis |
8 |
|
cognition disorders - etiology |
8 |
|
corpus striatum |
8 |
|
delusions - diagnosis |
8 |
|
delusions - etiology |
8 |
|
diffusion tensor imaging |
8 |
|
discontinuation |
8 |
|
dose-dependent effect |
8 |
|
drug-naive |
8 |
|
eye-gaze perception |
8 |
|
first episode psychosis |
8 |
|
fractional anisotropy |
8 |
|
growth mixture modeling |
8 |
|
interview, psychological - methods |
8 |
|
latent class analysis |
8 |
|
long-term outcome |
8 |
|
mass screening |
8 |
|
mass screening - methods |
8 |
|
mentalization |
8 |
|
mode of onset |
8 |
|
neuropsychological tests |
8 |
|
pandemic |
8 |
|
panss |
8 |
|
persistent psychotic experience |
8 |
|
prospective study |
8 |
|
psychotic disorder |
8 |
|
psychotic disorders - complications |
8 |
|
ptsd symptoms |
8 |
|
raclopride |
8 |
|
review |
8 |
|
schizophrenia - complications |
8 |
|
schizophrenia - pathology |
8 |
|
self-discrepancy |
8 |
|
semantic |
8 |
|
temporal lobe - ultrastructure |
8 |
|
trauma exposure |
8 |
|
adult |
7 |
|
age factors |
7 |
|
anti-stigma campaigns |
7 |
|
antipsychotic agents - administration and dosage |
7 |
|
behavioral symptoms - etiology - psychology - therapy |
7 |
|
big five |
7 |
|
chinese |
7 |
|
cognitive structure |
7 |
|
content-dependent process |
7 |
|
course |
7 |
|
duration of untreated psychosis (dup) |
7 |
|
effort-cost computation |
7 |
|
endophenotype |
7 |
|
executive function - physiology |
7 |
|
extended early intervention |
7 |
|
first-episode schizophrenia spectrum disorder |
7 |
|
follow-up studies |
7 |
|
functional remission |
7 |
|
gender |
7 |
|
genotype |
7 |
|
health service accessibility |
7 |
|
help-seeking |
7 |
|
help‐seeking |
7 |
|
illness disclosure |
7 |
|
late-onset psychosis |
7 |
|
latent class growth analysis |
7 |
|
long-term follow-up |
7 |
|
longitudinal |
7 |
|
longitudinal course |
7 |
|
male |
7 |
|
maternal age |
7 |
|
medication-naïve |
7 |
|
mental health literacy |
7 |
|
mental health services - organization and administration |
7 |
|
meta-analysis |
7 |
|
mindfulness |
7 |
|
motivational impairment |
7 |
|
network analysis |
7 |
|
neurobiology |
7 |
|
neuropsychology |
7 |
|
nomenclature |
7 |
|
overcontrolled |
7 |
|
paternal age |
7 |
|
pathways |
7 |
|
persistent primary negative symptoms |
7 |
|
personality |
7 |
|
prediction |
7 |
|
predictive value of tests |
7 |
|
prognosis |
7 |
|
psychosocial |
7 |
|
psychotherapy - methods |
7 |
|
psychotic disorders - diagnosis - drug therapy - therapy |
7 |
|
psychotic disorders - diagnosis - psychology |
7 |
|
ptsd symptoms, women mental health |
7 |
|
real-world functioning |
7 |
|
rehospitalization |
7 |
|
remission induction |
7 |
|
resilient |
7 |
|
schizophrenia - complications - diagnosis - epidemiology - therapy |
7 |
|
schizophrenia - diagnosis |
7 |
|
sex characteristics |
7 |
|
sex factors |
7 |
|
six elements |
7 |
|
sociodemographic correlates |
7 |
|
stability |
7 |
|
stigmatization |
7 |
|
stressful life event |
7 |
|
suicide, attempted - psychology |
7 |
|
terminology as topic |
7 |
|
time factors |
7 |
|
treatment delay |
7 |
|
undercontrolled |
7 |
|
violence |
7 |
|
antipsychotic |
6 |
|
app |
6 |
|
asia |
6 |
|
attitude |
6 |
|
at‐risk mental state |
6 |
|
balloon analogue risk task |
6 |
|
blinking |
6 |
|
categorization |
6 |
|
category fluency |
6 |
|
chinese zodiac signs |
6 |
|
chizophrenia |
6 |
|
clinical high‐risk |
6 |
|
clinical predictors |
6 |
|
clozapine |
6 |
|
clozapine-resistant schizophrenia |
6 |
|
cognitive clusters |
6 |
|
cognitive flexibility |
6 |
|
cognitive heterogeneity |
6 |
|
cognitive insights |
6 |
|
community |
6 |
|
compliance |
6 |
|
concepts |
6 |
|
cultural sensitivity |
6 |
|
culture |
6 |
|
delivery of health care - standards |
6 |
|
depressive mood |
6 |
|
development |
6 |
|
dibenzothiazepines - therapeutic use |
6 |
|
digit symbol test |
6 |
|
digital technologies |
6 |
|
double-blind method |
6 |
|
early intervention service |
6 |
|
early medical intervention - standards |
6 |
|
effort allocation |
6 |
|
effort discounting |
6 |
|
effort-based decision-making |
6 |
|
ethnic minority |
6 |
|
fitmind |
6 |
|
fractionation |
6 |
|
global functioning |
6 |
|
guideline |
6 |
|
history |
6 |
|
hospitalization |
6 |
|
human |
6 |
|
illness attributional belief |
6 |
|
immersive |
6 |
|
incidence |
6 |
|
internal feed-forward |
6 |
|
labelling |
6 |
|
letter |
6 |
|
long-term trajectories |
6 |
|
longitudinal negative symptoms |
6 |
|
mental health services - standards |
6 |
|
meta analysis |
6 |
|
mhealth |
6 |
|
mindfulness-based intervention |
6 |
|
negative treatment attitude |
6 |
|
neurocognition |
6 |
|
outcomes |
6 |
|
paranoid schizophrenia |
6 |
|
passivity experiences |
6 |
|
path analysis |
6 |
|
pilot |
6 |
|
pilot trial |
6 |
|
predictive validity |
6 |
|
primary negative symptoms |
6 |
|
priority journal |
6 |
|
prodrome |
6 |
|
psychiatric comorbidity |
6 |
|
psychoeducation |
6 |
|
psychosocial functioning |
6 |
|
psychotic disorders - drug therapy |
6 |
|
recommendation |
6 |
|
reliability |
6 |
|
risk aversion |
6 |
|
risk taking |
6 |
|
risky–gains task |
6 |
|
schizophrenia-spectrum disorder |
6 |
|
self-monitoring |
6 |
|
smartphone |
6 |
|
social functioning |
6 |
|
subjective quality of life |
6 |
|
switching |
6 |
|
symptomatic remission |
6 |
|
systematic review |
6 |
|
treatment |
6 |
|
treatment resistant schizophrenia |
6 |
|
treatment-resistant schizophrenia |
6 |
|
ultra-high risk |
6 |
|
validation |
6 |
|
virtual reality |
6 |
|
vocational outcome |
6 |
|
vr |
6 |
|
web-based |
6 |
|
working memory |
6 |
|
10-year follow-up |
5 |
|
10-year outcomes |
5 |
|
1st episode |
5 |
|
adolescent onset |
5 |
|
adult onset |
5 |
|
affiliate stigma |
5 |
|
aggressive behavior |
5 |
|
alogia |
5 |
|
anhedonia |
5 |
|
asian network for early psychosis |
5 |
|
asociality |
5 |
|
at-risk mental state |
5 |
|
attitudes towards medication |
5 |
|
auditory cortex |
5 |
|
auditory hallucination |
5 |
|
behavior |
5 |
|
blunted affect |
5 |
|
brain size |
5 |
|
caregiver |
5 |
|
caregivers’ distress |
5 |
|
case management |
5 |
|
chinese population |
5 |
|
cognition disorders - psychology |
5 |
|
community mental health service |
5 |
|
community mental health services - organization and administration - utilization |
5 |
|
cortical thickness (brain) |
5 |
|
dangerous |
5 |
|
diagnostic specificity |
5 |
|
discrimination |
5 |
|
disease severity |
5 |
|
drug knowledge |
5 |
|
early detection |
5 |
|
early medical intervention |
5 |
|
exercise |
5 |
|
express emotion |
5 |
|
face concern |
5 |
|
family caregiver |
5 |
|
financial deprivation |
5 |
|
first psychosis |
5 |
|
first-episode mania |
5 |
|
firstepisode psychosis |
5 |
|
first‐episode psychosis |
5 |
|
follow-up study |
5 |
|
formal thought disorder |
5 |
|
gad-7 |
5 |
|
gender effect |
5 |
|
general self-efficacy |
5 |
|
genetic high-risk |
5 |
|
glucose supplement |
5 |
|
health-care professionals' attitude |
5 |
|
hopelessness |
5 |
|
knowledge about psychosis |
5 |
|
knowledge of medication |
5 |
|
language |
5 |
|
language disorganization |
5 |
|
learned irrelevance |
5 |
|
media |
5 |
|
media report violent |
5 |
|
mediators |
5 |
|
medication |
5 |
|
medication discontinuation |
5 |
|
medication knowledge |
5 |
|
meta-aggregation |
5 |
|
metabolic screening |
5 |
|
metabolic syndrome |
5 |
|
neurocognitive impairment |
5 |
|
neurological examination abnormalities |
5 |
|
newspapers |
5 |
|
patient demographics |
5 |
|
perceived public stigma |
5 |
|
polypharmacy |
5 |
|
positive symptoms |
5 |
|
program |
5 |
|
programme evaluation |
5 |
|
psychiatry |
5 |
|
psychotic disorders - diagnosis - drug therapy - psychology |
5 |
|
psychotic symptoms |
5 |
|
psychotic-like experience |
5 |
|
public awareness |
5 |
|
qualitative |
5 |
|
qualitative systematic review |
5 |
|
rasch model |
5 |
|
relapse risk perception |
5 |
|
schizophrenia, pandemic |
5 |
|
schizophrenia-spectrum disorders |
5 |
|
school-based programme |
5 |
|
selective attention |
5 |
|
severity of illness index |
5 |
|
social contact |
5 |
|
social stigma |
5 |
|
stigma reduction |
5 |
|
suicidal behavior |
5 |
|
suicidal ideation |
5 |
|
suicide attempt |
5 |
|
symptoms |
5 |
|
syntax |
5 |
|
trait |
5 |
|
trial |
5 |
|
validity |
5 |
|
video |
5 |
|
youth and adult |
5 |
|
youth psychosis |
5 |
|
flow model of rumination |
4 |
|
hippocampus |
4 |
|
memory |
4 |
|
psychotherapy |
4 |
|
public health emergency |
4 |
|
salience |
4 |
|
technological advances |
4 |
|
treatment response |
4 |
|
aerobic exercise |
3 |
|
communication |
3 |
|
hayling |
3 |
|
needs assessment |
3 |
|
physician-patient relations |
3 |
|
questionnaires |
3 |
|
structural neuroimaging |
3 |
|
temporal cortex |
3 |
|
yoga |
3 |
|
computational semantics |
2 |
|
ht1001 |
2 |
|
longitudinal study |
2 |
|
neurological soft signs |
2 |
|
north american ginseng extract |
2 |
|
schizophrenia - prognosis. |
2 |
|
schizophrenia - relapse. |
2 |
|
semantic networks |
2 |
|
at-risk-mental-state |
1 |
|
high-risk |
1 |
|
psychotic-like |
1 |
